Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEMECAN Oktonia Typ 2
- Development stage
- Unknown
- Lead developer
- DEMECAN
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Sublingual
01
Overview
DEMECAN Oktonia Typ 2 is a line of medical cannabis full-spectrum extracts developed and manufactured by DEMECAN, a German cannabis company. The extracts are derived from Sativa-dominant 'Typ 2' cannabis plants (cultivar: DEMECAN TWO, strain: Orange Velvet) grown in Germany for the BfArM (German Federal Institute for Drugs and Medical Devices), using supercritical CO2 extraction. The active ingredients are THC (tetrahydrocannabinol) and CBD (cannabidiol), and the product line comes in multiple formulations with varying THC:CBD ratios (such as 25:1, 10:10, 5:20, and 30:1). MCT oil is used as the carrier oil. The extracts are administered sublingually via a dosing pipette and are prescription-only. The biological targets are the endocannabinoid receptors (CB1 and CB2), consistent with THC and CBD pharmacology. Reported therapeutic indications include stress, depression, and anxiety.
- Brand names
- DEMECAN Oktonia Typ 2Oktonia Typ 2
- Other names
- DEMECAN Oktonia Typ 2 05:20DEMECAN Oktonia Typ 2 10:10DEMECAN Oktonia Typ 2 25:01DEMECAN Oktonia Typ 2 30:01DEMECAN TWO
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on DEMECAN Oktonia Typ 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEMECAN Oktonia Typ 2.